1. Kuehn Law is investigating Sarepta Therapeutics' fiduciary duties. 2. SEC lawsuit claims insiders misled shareholders regarding ELEVIDYS safety risks. 3. Adverse events from ELEVIDYS may halt trials and attract regulatory scrutiny. 4. Shareholders who bought SRPT before June 22, 2023, should contact Kuehn Law. 5. This litigation could significantly affect SRPT's market perception and stock price.
Legal investigations and lawsuits can severely undermine investor confidence, as seen with other biotech firms facing similar issues. Such impacts can lead to declining stock prices, exemplified by past incidents of biotech companies halting trials after safety concerns.
The investigation into fiduciary duties and potential misrepresentation may substantially affect investor trust and future FDA approvals. Given the issues around ELEVIDYS, the potential for significant share price fluctuations is high.
The immediate effect of a federal lawsuit can cause stock volatility. Past examples show stocks react swiftly to news of litigation, leading to short-term price drops.
NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Sarepta Therapeutics caused the company to misrepresent or fail to disclose that (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, insiders materially misled with, and/or lacked a reasonable basis for, their positive statements.
If you currently own SRPT and purchased prior to June 22, 2023 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-sarepta-therapeutics-inc-to-contact-law-firm-302566061.html
SOURCE Kuehn Law, PLLC